Spedizione gratuita per ordini superiori a 69,99 euro.

Controllare lo stato dell'ordine

Entra a far parte di una comunità di amanti dei libri di tutto il mondo e ottieni numerosi vantaggi. Crea un account gratuito

Spedizione gratuita con Packeta per un prezzo superiore a 69.99 €

Bartolini 4.49 € Punto Poste 5.49 € Punto Poste 5.49 € Punto Bartolini 3.49 € DHL 6.99 € GLS 5.99 €

Contatto

Come acquistare

Aiuto

Il mio account

▸ Vuoto :-(

Spedizione gratuita per ordini superiori a 69,99 euro.

Activity-based proteomics

Name: Activity-based proteomics
Brand: Sudwestdeutscher Verlag Fur Hochschulschriften AG
SKU: 07148241
Price: 50.29 EUR
Availability: InStock
Author: Thomas Wiedl
ISBN: 9783838131375

Thomas Wiedl

Lingua

Inglese

Libro In brossura

Codice Libristo: 07148241

Casa editrice Sudwestdeutscher Verlag Fur Hochschulschriften AG, febbraio 2012

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ra... Descrizione completa

Codice Libristo: 07148241

123 b

50.29 €

Magazzino esterno Inviamo tra 8-11 giorni

30 giorni per il reso

I clienti hanno acquistato anche

Oscar Wilde's "Dorian Gray" in drei deutschen Übersetzungen Corinna Clauß

In brossura

51.99 €

Zulassigkeit der Nothwehr gegenuber beleidigenden AEusserungen, Leopold Bauke

In brossura

12.29 €

Šumava krásná a tajemná Martin Čihař

Rigido

16.59 €

Legislacion de marcas, patentes y diseño industrial RICARDO ALONSO

Rigido

70.39 €

Fosilie Michal Kašpárek

In brossura

9.09 €

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ranges from 80% in early stages to less than 5% in advanced disease. Non-small cell lung carcinoma (NSCLC) accounts for 80% of all lung malignancies, 40% of which are adenocarcinomas representing one of the most common lung cancer subtypes. Currently, prognosis is mostly determined based on the extension of disease at diagnosis. Thereby it has become evident that predicted and real outcomes can vary significantly, even for patients with the same stage of disease. Thus, novel biomarkers that refine prognosis with a reliable clinical significance are clearly needed. Therefore we aimed to implement an activity-based proteomics platform representing a powerful tool in the search for novel disease biomarkers.